Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status

References

• Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem. 2004;11:2033–2043.
   Google Scholar
• Riederer P, Müller T. Monoamine oxidase-B inhibitors in the treatment of Parkinson‘s disease: clinical-pharmacological aspects. J Neural Transm (Vienna). 2018;125(11):1751–1757.
   Google Scholar
• Stocchi F, Olanow CW. Neuroprotection in Parkinson‘s disease: clinical trials. Ann Neurol. 2003;53(Suppl 3):S87–S97.
   Google Scholar
• Riederer P, Müller T. Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin Drug Metab Toxicol. 2017;13:233–240.
   Google Scholar
• Konradi C, Riederer P, Jellinger K, et al. Cellular action of MAO inhibitors. J Neural Transm Suppl. 1987;25:15–25.
   Google Scholar
• Riederer P, Laux G. MAO-inhibitors in Parkinson‘s disease. Exp Neurobiol. 2011;20:1–17.
   Google Scholar
• Nishida K, Itoh S, Inoue N, et al. High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users. J Anal Toxicol. 2006;30:232–237.
   Google Scholar
• Müller T, Hoffmann JA, Dimpfel W, et al. Switch from selegiline to rasagiline is beneficial in patients with Parkinson‘s disease. J Neural Transm. 2013;120:761–765.
   Google Scholar
• Reynolds GP, Elsworth JD, Blau K, et al. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol. 1978;6:542–544.
   Google Scholar
• Bartl J, Müller T, Grünblatt E, et al. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm. 2014;121:379–383.
   Google Scholar
• Burke WJ, Li SW, Chung HD, et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology. 2004;25:101–115.
   Google Scholar
• Burke WJ, Kumar VB, Pandey N, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008;115:193–203.
   Google Scholar
• Panneton WM, Kumar VB, Gan Q, et al. The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One. 2010;5:e15251.
   Google Scholar
• Bar-Am O, Weinreb O, Amit T, et al. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005;19:1899–1901.
   Google Scholar
• Weinreb O, Amit T, Bar-Am O, et al. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann N Y Acad Sci. 2007;1122:155–168.
   Google Scholar
• Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem. 2002;82:913–923.
   Google Scholar
• Akao Y, Maruyama W, Yi H, et al. An anti-Parkinson‘s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002;326:105–108.
   Google Scholar
• Naoi M, Riederer P, Maruyama W. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J Neural Transm (Vienna). 2016;123:91–106.
   Google Scholar
• Teo KC, Ho SL. Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson‘s disease. Transl Neurodegener. 2013;2:19.
   Google Scholar
• Birkmayer W, Riederer P. Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson‘s disease. Adv Neurol. 1984;40:475–481.
   Google Scholar
• Hoy SM, Keating GM. Rasagiline: a review of its use in the treatment of idiopathic Parkinson‘s disease. Drugs. 2012;72:643–669.
   Google Scholar
• Rascol O. Rasagiline in the pharmacotherapy of Parkinson‘s disease–a review. Expert Opin Pharmacother. 2005;6:2061–2075.
   Google Scholar
• Müller T, Foley P. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide. Clin Pharmacokinet. 2017;56:251–261.
   Google Scholar
• Al-Nuaimi SK, MacKenzie EM, Baker GB. Monoamine oxidase inhibitors and neuroprotection: a review. Am J Ther. 2012;19:436–448.
   Google Scholar
• Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem. 2007;103:500–508.
   Google Scholar
• Eliash S, Dror V, Cohen S, et al. Neuroprotection by rasagiline in thiamine deficient rats. Brain Res. 2009;1256:138–148.
   Google Scholar
• Parkinson Study Group. Variable expression of Parkinson‘s disease: a base-line analysis of the DATATOP cohort. Neurology. 1990;40(19):1529–1534.
   Google Scholar
• Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson‘s disease in DATATOP patients requiring levodopa. Ann Neurol. 1996;39:37–45.
   Google Scholar
• Przuntek H, Conrad B, Dichgans J, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol. 1999;6:141–150.
   Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson‘s disease. N Engl J Med. 2009;361:1268–1278.
   Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol. 2002;59:1937–1943.
   Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561–566.
   Google Scholar
• Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson‘s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000;23:324–330.
   Google Scholar
• Elmer LW. Rasagiline adjunct therapy in patients with Parkinson‘s disease: post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord. 2013;19:930–936.
   Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241–248.
   Google Scholar
• Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson‘s disease and motor fluctuations (LARGO, Lasting effect in adjunct therapy with Rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947–954.
   Google Scholar
• Müller T. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson‘s disease. Expert Opin Drug Metab Toxicol. 2014;10:1423–1432.
   Google Scholar
• Müller T. Safinamide: an add-on treatment for managing Parkinson‘s disease. Clin Pharmacol. 2018;10:31–41.
   Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson‘s disease. Mov Disord. 2014;29:1273–1280.
   Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson‘s disease with motor fluctuations. Mov Disord. 2014;29:229–237.
   Google Scholar
• Schapira AV,Fox SH, HauserRA. Et Al. Assessment Of Safety and Efficacy Of Safinamide as a Levodopa Adjunct in Patient with Parkinson Disease and Motor Fluctuations. a Randomized Clinical Trial. Jama Neurol. 2017;74(2):216–224.
   Google Scholar
• Liedhegner EA, Steller KM, Mieyal JJ. Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson‘s disease. Chem Res Toxicol. 2011;24:1644–1652.
   Google Scholar
• Sabens EA, Distler AM, Mieyal JJ. Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: implications for therapy of Parkinson‘s disease. Biochemistry. 2010;49:2715–2724.
   Google Scholar
• Müller T, Trommer I, Muhlack S, et al. Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson‘s disease. J Neural Transm (Vienna). 2016;123:401–406.
   Google Scholar
• Müller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson‘s disease. Expert Rev Neurother. 2013;13:707–718.
   Google Scholar
• Müller T. Catechol-O-methyltransferase inhibitors in Parkinson‘s disease. Drugs. 2015;75:157–174.
   Google Scholar
• Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized delayed-start trial of Levodopa in Parkinson‘s Disease. N Engl J Med. 2019;380:315–324.
   Google Scholar